Table 2.
Reference | Study design | Population Sample (n) RA outcomes (n) |
COPD exposure methods |
RA outcome methods |
Smoking and other adjustment variables |
Effect size (95% confidence interval) for COPD and RA risk (reference group: no COPD) |
Comments |
---|---|---|---|---|---|---|---|
De Roos AJ, Ann Epidemiol (2008) [81] | Case-control | Iowa & North Carolina, pesticide applicators and spouses (Agricultural Health Study) n=810 n=135 RA |
Self-report (chronic bronchitis) | Physician-confirmed | No smoking adjustment Age, US state |
Prevalent RA: OR 0.8 (0.3-2.2) Incident RA: OR 1.3 (0.3-5.7) |
Cases were mostly prevalent RA; limited sample size and adjustment variables; also investigated other personal and family medical conditions |
Bergström U, Rheumatology (2011) [97] | Nested case-control | Sweden (Malmö Preventive Medicine Program) n=1,450 n=290 incident RA |
Presence and severity by GOLD criteria from research pulmonary function testing | Medical record review meeting 1987 ACR criteria | Smoking adjustment: not current/current Age, sex, socioeconomic status |
Mild/stage I COPD: OR 1.34 (0.67-2.68) Moderate to very severe/stages II-IV COPD: OR 1.08 (0.59-1.99) |
Pulmonary function tests were measured prospectively prior to RA diagnosis; suggestion of increased risk for RA among women with COPD, but not men; limited sample size and adjustment variables; also investigated restrictive lung disease |
Sheen YH, J Allergy Clin Immunol Pract (2018) [75] |
Case-control | Olmsted County, Minnesota (Rochester Epidemiology Project) n=439 n=221 RA |
Not described | Billing and Berkson codes | No smoking adjustment No covariates |
OR 0.62 (0.32-1.23) | Only unadjusted COPD results reported in this study that was focused on asthma; limited sample size |
ACR, American College of Rheumatology; COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for Obstructive Lung Disease; OR, odds ratio; RA, rheumatoid arthritis.